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CASE REPORT
Blinatumomab may induce graft versus host leukemia in
patients with pre-B ALL relapsing after hematopoietic stem
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Key Clinical Message
Blinatumomab, a bispecific T-cell engager monoclonal antibody used to manage
Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute
lymphoblastic leukemia (ALL) can be used to treat patients by inducing graft
versus leukemia reaction post allogeneic hematopoietic stem cell transplanta-
tion, a feature which it was post allogeneic bone marrow transplantation, a fea-
ture which this drug was not aimed to do.
Keywords
BiTe antibody in ALL, blinatumomab in pre-B ALL, post transplant ALL
management, refractory ALL treatment.
Case
A 61-year-old female was diagnosed with Pre-B ALL (MLL
positive, mixed lineage leukemia) CNS negative, relapsed
after HyperCVAD and was refractory to Asparaginase, Vin-
cristine, Dexamethasone (Capizzi regimen) followed by
Cytoxan/Etoposide (Cytoxan dose 50 mg/kg intravenous on
days 3–5; Etoposide (VP16) dose 600 mg/m2 intravenous
every 8 h, with four doses started on day 2 of treatment).
She achieved remission with 9 lg dose Blinatumomab; a
grade 3 neurological toxicity is usually seen with 28 lg doses
(Table 1). She was subsequently transplanted in molecular
remission from a matched sibling donor using Busulfan
(AUC 4800) and Fludarabine (30 mg/m2 on days 1–5). She
received Tacrolimus, Methotrexate, and Rituximab for
GVHD prophylaxis (graft versus host disease). On the 100th
evaluation day, she relapsed with a loss of donor chimerism
to 43% without evidence of GVHD.
Blinatumomab was restarted at lower dose of 9 lg and
molecular remission was achieved. It was held after two
cycles because she developed nausea, diarrhea, and ele-
vated liver enzymes (ALT-820U/L; ALP-243U/L). It was
noted that she had a 100% donor chimerism and the
biomarkers for GVHD had increased especially REG3
alpha (Regenerating islet-derived protein 3 alpha-a gene
encoding pancreatic secretory protein that is involved in
cellular differentiation and proliferation) that increased to
217 ng/mL. She was started on prednisone at 1 mg/Kg
(25 mg daily) which resulted in resolution of her symp-
toms and decrease in levels of REG 3 alpha (88 ng/mL
[Normal <74 ng/mL]). She gained weight and her liver
enzymes reduced to near normal (ALT 67U/L). Pred-
nisone was tapered to 10 mg PO daily. She is currently
day 240 post-transplant and is in remission with a 100%
donor chimerism (Fig. 1).
Discussion
Adult acute lymphoblastic leukemia remains a challenging
disease to treat with precursor-B ALL comprising nearly
80% of cases [1].
This aggressive lymphoid malignancy comprises of the
replacement of the cells present in the bone marrow com-
partment with blasts cells. Although ALL may have several
phenotypic presentations, precursor B-cell (pre-B) ALL is
the most common phenotype present [1]. Multidrug
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chemotherapy regimens followed by a consolidation phase
with high-dose chemotherapy is the initial stage of treat-
ment during the management of this disease. A second
intensive regimen is often administered, which is generally
followed by a few years of low-dose maintenance
chemotherapy in those not proceeding to allogeneic
hematopoietic stem cell transplant (HSCT).
The CD19 antigen is expressed in almost all precursor-
B ALL patients, hence representing an interesting target
for therapeutic research. Blinatumomab, a bispecific T-
cell-engaging (BiTE) monoclonal antibody engages poly-
clonal T cells to CD19-expressing B cells by binding to
both CD3 and CD19. It brings them in close quarters to
the malignant B cells, potentiating T-cell-induced cyto-
toxic activity [2, 3]. BiTE antibodies are genetically con-
structed single chain antibodies that use a recombinant
linked nonimmunogenic five-amino acid chain that com-
bines two variable regions of a normal antibody with dif-
ferent specificities (scFvs [single-chain variable fragment]
on CD19 and CD3 on T cells) [3]. This connector allows
a high degree of flexibility in rotation that will be needed
for binding each of the CD3 and CD19 epitopes on cell
membranes. The polyclonal T-cell population creates an
antitumor response [3]. BiTE antibodies direct a T-cell
cytotoxic response by not targeting the major histocom-
patibility complexes which are often downregulated on
tumor cells, regardless of their tumor immune escape
mechanisms.
Blinatumomab was initially evaluated in B-cell non-
Hodgkin’s lymphoma (NHL) and in B-cell ALL [4, 5].
Cytokine-release syndrome (CRS), a known adverse event
with blinatumomab therapy is usually characterized by
Table 1. Grading of chemotherapy-induced peripheral neuropathy
Scale Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
ECOG [11] None Mild paresthesisas
Decreased deep tendon
reflex
Severe paresthesias
Absent deep tendon
reflex
Disabling sensory loss
Severe peripheral
neuropathic pain
Bladder dysfunction
Respiratory dysfunction
secondary to weakness
Paralysis
WHO [12] None Paresthesias
Decreased tendon
reflexes
Severe paresthesias
Mild weakness
Intolerable paresthesias
Marked motor loss
Paralysis
Patient diagnosed 
with pre-B ALL
Relapsed
Treated with hyperCVAD followed 
by etoposide and cytoxan
Relapsed
Blinatumomab
Relapsed
(donor chimerism 43%)
HSCT
Blinatumomab restarted
Remission
(donor chimerism 100%)
Figure 1. Timeline indicating sequence of events.
744 ª 2016 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
Blinatumomab in pre-B ALL M. W. Khan & Z. Gul
fevers, chills, and hypotension that may or may not be asso-
ciated dyspnea in severe cases. This syndrome is due to the
rapid malignant cell destruction by T lymphocytes during
the initial infusion. Fever may be seen in up to 70% of the
patients treated [4, 5]. Pretreatment with steroids decreases
the severity of this syndrome. Central nervous system
events (CNS-seizures and encephalopathy) have also been
reported in almost 20% of patients, though all CNS events
were reversible upon withholding the drug [5]. Hypogam-
maglobulinemia, leukopenia with neutropenia, and B-cell
lymphocytopenia may frequently be encountered in
patients treated with blinatumomab [6].
In a study by Topp et al. [7] in 2012, 36 patients with
relapsed or refractory B-cell ALL in a phase II trial were
evaluated. Three groups were evaluated in an intrapatient
dose escalation manner with an optimal determined
dosage of 5 lg/m2/24 h in week 1, and 15 lg/m2/24 h on
subsequent weeks and cycles. CNS events and CRS were
common at higher doses during initial treatment due to
the high tumor burden [7]. Hematologic complete remis-
sion (CR) was achieved in 72% (26 patients). CR was
more common in patients with first relapse (95% CR
rate; 20 out of 21 patients) than those treated after subse-
quent relapse (40% CR rate; six out of 15 patients). Allo-
geneic hematopoietic stem cell transplant (HSCT) was
performed in 13 of the 26 responders with a median fol-
low-up 10.7 months [7]. Overall, the median survival was
9.8 months, with a 14.1-month median survival in
responders. In comparison with the median survival of
24 weeks in relapsed ALL with chemotherapy, blinatu-
momab demonstrated superior efficacy [8].
We hypothesize that suppression of CD 19-positive B
cells may induce suppression of B regulatory cells which
in turn may lead to decrease T regulatory cells, thus lead-
ing to graft versus leukemia (GVL) effect, manifesting as
GVHD [9, 10]. We suggest that blinatumomab might play
a role in maintenance therapy after allogeneic HSCT and
warrants prospective assessment.
Conclusion
In summary, we would like to report a case of pre-B
ALL with aggressive course refractory to multiple lines
of therapy including hematopoietic stem cell transplant
that responded to blinatumumab, resulting in complete
donor chimerism and induction of GVHD that
responded to steroids and remains quiescent with ster-
oid taper. From our literature search, this is the first
relapsed patient reported after allogeneic HSCT that
attained full donor chimerism, induction of GVL as
manifested by mild GVHD, and complete remission
with blinatumomab which shows potential of this
strategy as maintenance therapy after allogeneic HSCT
in this patient population.
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